News

Innovative Suprachoroidal Injector to Transform Retinal Treatments

Innovative Suprachoroidal Injector to Transform Retinal Treatments

New Developments in Retinal Disease Treatments

Everads Therapy, a clinical-stage company focused on retinal disease treatments, is making significant strides with its innovative suprachoroidal delivery technology. This advance has attracted attention due to its potential to revolutionize how conditions like retinal detachments are treated. Recently, Everads announced two exciting oral presentations at the 2025 American Society of Retina Specialists (ASRS) Annual Meeting, showcasing the full results from their first-in-human clinical trial and new preclinical findings.

Clinical Study Highlights

The clinical trial evaluated the Everads Injector's safety and performance for administering a triamcinolone acetonide suspension via the suprachoroidal route in patients dealing with diabetic macular edema. The results were promising, confirming the safety, feasibility, and an overall user-friendly experience for the injector used in an office-based setting.

Executive Chairman, Moshe Weinstein, expressed his enthusiasm: "We're excited to share the full dataset from our clinical trial, demonstrating the safety, tolerability, and performance of our suprachoroidal injector, along with new data supporting its potential use for in-office retinal detachment repair." These findings lay a solid groundwork for advancing future programs utilizing this pioneering delivery platform.

Expanding Treatment Options for Retinal Detachments

As retinal detachment repair presents continuing complexities, there is a pressing need for less invasive and more affordable treatment options. This shift aims to enhance patient recovery durations significantly. In a preclinical study conducted using human cadaver eyes, Dr. Gareth D. Mercer and his colleagues highlighted the Everads Injector's capability to successfully administer viscoelastic substances into the suprachoroidal space. Their results demonstrated a reliable relationship between the volume injected and the size of the resulting buckle, underscoring the technology's innovative potential in non-surgical, in-office interventions.

Upcoming Presentations at ASRS 2025

Attendees at the conference can look forward to two key presentations from Everads:

  • Minimally Invasive Suprachoroidal Buckling Using a Novel Injector: Preclinical Evaluation in Human Cadaver Eyes
    Presented by Mercer GD et al on July 31st at 8:28 AM in Hall B
  • First-in-Human Study Using a Novel Suprachoroidal Injector
    Presented by Barak Y et al on August 2nd at 4:27 PM in Hall B

About Everads Therapy

Everads Therapy is committed to transforming retinal disease treatment with its proprietary suprachoroidal delivery platform. This platform facilitates swift, broad, and secure drug distribution via non-invasive, office-based injections. Furthermore, the company is actively developing this approach for in-office suprachoroidal buckling (viscopexy) aimed at treating selected retinal detachments. Collaboration with partners spans gene therapy, cell therapy, and various small molecule formulations, all aimed at optimizing the capabilities of this advanced delivery system.

Company Background

Established as a spin-out from DALI Medical Devices, which is recognized for its expertise in injectable drug delivery technologies, Everads is nestled within RAD Biomed, a well-respected biotech accelerator. Its cutting-edge technologies are licensed from the laboratory headed by Prof Y Rotenstreich at the Sheba Tel Hashomer Medical Center.

For further updates and information about Everads Therapy, visit their website.

Frequently Asked Questions

What new findings did Everads present at ASRS 2025?

Everads shared the full results from their first-in-human clinical trial and preclinical data supporting their suprachoroidal injector for retinal treatments.

What is the Everads Injector?

The Everads Injector is a novel device designed for suprachoroidal drug delivery, aiming to treat conditions like diabetic macular edema and retinal detachments with minimal invasiveness.

Why is the suprachoroidal delivery method important?

This method offers a safer, more effective way to administer medications directly to the retinal area, enhancing patient comfort and potentially improving recovery times.

What did the preclinical studies demonstrate?

Preclinical studies showed that the Everads Injector can reliably deliver viscoelastic substances into the suprachoroidal space, indicating its efficacy for treating retinal detachment.

How is Everads Therapy positioned in the industry?

Everads Therapy is at the forefront of retinal disease treatment, innovating with its proprietary technologies and collaborating with various partners in the biotech field.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 201

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 296

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Robinhood Markets Shares November 2025 Operational Highlights

Updated Category News Views 269

Robinhood Markets Releases November 2025 Operational Highlights Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) has recently shared its monthly operating data for November 2025, offering an insightful look into its operational metrics and customer engagement. This report emphasizes key growth indicators and trading volume achievements over the month, reflecting...

Continue Reading
Gold Prices Decline Amid Anticipation of Federal Reserve Actions

Updated Category News Views 140

Gold Prices Drop as Federal Reserve Meeting Commences Gold prices experienced a decline as traders adjusted their positions ahead of the Federal Reserve's crucial meeting. The latest updates signal a decrease in spot gold prices, which now hover around $2,646.06 an ounce. Similarly, gold futures, set to expire in February, showed a minor drop to $2,662.44 an ounce. This...

Continue Reading
Understanding Adobe's Current Stock Performance Analysis

Updated Category News Views 239

Market Dynamics of Adobe Inc. Investors are taking a closer look at Adobe Inc (NASDAQ: ADBE) as they adopt varying strategies in the options market. Notably, deep-pocketed investors have shown bearish tendencies, making it a key point of interest for those monitoring market movements. Recent observations have highlighted an unusual upsurge in options activities related to...

Continue Reading
NexPoint Diversified Real Estate Trust's New Preferred Share Offering

Updated Category News Views 212

NexPoint Diversified Real Estate Trust Announces Major Offering NexPoint Diversified Real Estate Trust (NYSE: NXDT), a leading player in the real estate investment trust sector, has unveiled an opportunity for investors with a continuous public offering of its 9.00% Series B Cumulative Redeemable Preferred Shares. With a planned issuance of up to 16,000,000 shares, the...

Continue Reading
Outbrain Dominates the Q4 2024 France Ad Seller Rankings

Updated Category News Views 185

Outbrain Leads the Way in France's Q4 2024 Ad Rankings In a recent release, Pixalate has highlighted the leading programmatic ad sellers in France for the fourth quarter of 2024. This report emphasizes the importance of quality within the digital advertising ecosystem, offering a glimpse into the companies making significant strides in this sector. Understanding the...

Continue Reading